Heterozygous APOE Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes.
Isabel HernandezEllen GelpíLaura Molina-PorcelSara BernalBenjamín Rodríguez-SantiagoOriol Dols-IcardoAgustín RuizDaniel AlcoleaMercè BoadaAlberto LleóJordi ClarimónPublished in: Neuropathology and applied neurobiology (2020)
We present the clinical and neuropathological findings of a patient with early onset Alzheimer's dementia (AD), heterozygous carrier of the rare Apolipoprotein E Christchurch (APOEch) variant. The patient did not harbor any pathogenic mutation in known Mendelian genes related to AD or other neurodegenerative disorders. A sibling of this patient, also carrying the APOEch variant, developed AD at the age of 66 years old. Our data suggest a possible deleterious effect of this variant, which contrast with the protective role that has been previously shown in a subject homozygous for the APOEch with he Paisa PSEN1 mutation.